Literature DB >> 33507447

Impact of genetic variants in IL-2RA and IL-2RB on breast cancer risk in Chinese Han women.

Lingge He1, Wenjie Zhang2, Shuangyu Yang2, Wenting Meng2, Xia Dou2, Jianfeng Liu2, Yuanwei Liu2, Haiyue Li2, Tianbo Jin3,4,5.   

Abstract

The expression of IL-2RA and IL-2RB was correlated with breast cancer (BC) progression. However, there is no literature investigating the association of IL-2RA and IL-2RB polymorphisms with BC predisposition among Chinese Han Women. Seven SNPs in IL-2RA and IL-2RB were genotyped by Agena MassARRAY platform among 553 BC patients and 550 healthy controls. Odds ratios (OR) and 95% confidence interval (CI) adjusted for age were calculated for the effect of IL-2RA and IL-2RB variants on BC susceptibility. IL-2RA rs12722498 was a protective factor for BC occurrence (OR = 0.70, p = 0.019), especially in subjects with age ≤ 52 years (OR = 0.55, p = 0.004). IL-2RA rs12569923 (OR = 9.07, p = 0.033), IL-2RB rs2281089 (OR = 0.67, p = 0.043) and rs9607418 (OR = 0.59, p = 0.012) were related to the incidence of estrogen receptor positive (ER +) BC. IL-2RB rs3218264 (OR = 1.38, p = 0.010) and rs9607418 (OR = 0.56, p = 0.009) were associated with the risk of developing progesterone receptor positive (PR +) BC. Rs2281089 (OR = 1.54, p = 0.012) and rs1573673 (OR = 0.72, p = 0.035) were correlated to Ki-67 level. Moreover, IL-2RB rs2281089 (OR = 0.72, p = 0.022) showed a reduced risk of BC metastasis, and IL-2RA rs12722498 (OR = 0.54, p = 0.030) had a lower frequency in BC patients with tumor size > 2 cm. Our study identified the potential effect of genetic variations in IL-2RA and IL-2RB on BC susceptibility and/or BC clinicopathologic indicators among Chinese Han Women.

Entities:  

Keywords:  Breast cancer; Clinicopathologic indicators; IL-2RA; IL-2RB; Susceptibility

Year:  2021        PMID: 33507447     DOI: 10.1007/s10528-021-10029-y

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  32 in total

1.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

2.  The MassARRAY® System for Targeted SNP Genotyping.

Authors:  Justine A Ellis; Benjamin Ong
Journal:  Methods Mol Biol       Date:  2017

3.  Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: A case-control study.

Authors:  Yujiao Deng; Linghui Zhou; Na Li; Meng Wang; Li Yao; Shanshan Dong; Ming Zhang; Pengtao Yang; Qian Hao; Ying Wu; Lijuan Lyu; Tianbo Jin; Zhijun Dai; Huafeng Kang
Journal:  Mol Carcinog       Date:  2019-09-05       Impact factor: 4.784

Review 4.  The role of interleukin-2 during homeostasis and activation of the immune system.

Authors:  Onur Boyman; Jonathan Sprent
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

Review 5.  Epidemiology of Breast Cancer in Women.

Authors:  Steven S Coughlin
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 6.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

Authors:  D C Allred; J M Harvey; M Berardo; G M Clark
Journal:  Mod Pathol       Date:  1998-02       Impact factor: 7.842

7.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells.

Authors:  Amir Asgari; Sedigheh Sharifzadeh; Abbas Ghaderi; Ahmad Hosseini; Amin Ramezani
Journal:  Mol Biol Rep       Date:  2019-09-06       Impact factor: 2.316

Review 10.  Essential Oils from Neotropical Piper Species and Their Biological Activities.

Authors:  Joyce Kelly da Silva; Rafaela da Trindade; Nayara Sabrina Alves; Pablo Luís Figueiredo; José Guilherme S Maia; William N Setzer
Journal:  Int J Mol Sci       Date:  2017-12-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.